TORONTO, ONTARIO — (Aug 27, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, August 21 for the fiscal quarter ended June 30, 2015. The Corporation’s unaudited Q1 2016 financial statements and MD&A are available on SEDAR.

Antibe is performing validation studies in an effort to gain a better understanding of why the higher doses of ATB-346 caused damage to liver cells in some subjects in the Phase 1 clinical trial. Two potential mechanisms are being investigated. The first series of validation studies examined the possibility that ATB-346 is more potent than initially anticipated (i.e., lower than anticipated doses would produce significant inhibition of the target enzymes for anti-inflammatory activity). It is well established that all nonsteroidal anti-inflammatory drugs (NSAIDs) can cause damage to the liver in some patients, particularly at high doses. The market has been informed of the results from these studies in previous releases.

The second series of the validation studies examines the possibility that a metabolite of ATB-346 accumulates to high levels in the body (particularly in the liver) leading to tissue damage. ATB-346 consists of naproxen linked to a hydrogen sulfide-releasing molecule. Studies are being performed in rats using radiolabelled ATB-346, in which the hydrogen sulfide-releasing portion of the molecule is ‘tagged’ with radioactive carbon, thereby allowing it to be tracked after it is administered to each rat. The most recent data are from studies in which ATB-346 was administered daily for 4 days. There was no significant retention or accumulation of the radiolabelled portion of the drug in any tissues, with more than 99% being excreted in urine. Less than one-tenth of 1% of the radiolabel remained in the liver 8 hours after the final administration of ATB-346. Additionally, levels of retention of the radiolabel in other organs, including the kidney, stomach, small intestine and lungs, were extremely low. The studies are ongoing and the market will be updated as further data become available.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Contact Information

Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095

Read all news


This is an external link. Click “OK” to continue.